STUDY PARP inhibitor PHASE STATUS
Olaparib for patients with recurrent BRCA deficient ovarian cancer olaparib Phase 2 Withdrawn
AZD2281 Plus Carboplatin to treat breast and ovarian cancer AZD2281 Phase 1 Recruiting
A study to assess the safety and pharmacokinetics of an inhibitor of Poly-ADP-Ribose Polymerase-1 (PARP) AZD2281 Phase 1 Active, not recruiting
A single-arm study evaluating carboplatin/gemcitabine in combination with BSI-201 in patients with platinum-Sensitive recurrent ovarian cancer Iniparib Phase 2 Completed
A single-arm study evaluating carboplatin/gemcitabine in combination with BSI-201 in patients with platinum-resistant recurrent ovarian cancer Iniparib Phase 2 Completed
An open-label, multicenter, phase 1/2 study of Poly(ADP-ribose) Polymerase (PARP) Inhibitor E7449 as single agent in subjects with advanced solid tumors or with B-cell malignancies and in combination with Temozolomide (TMZ) or with Carboplatin and Paclitaxel in subjects with advanced solid tumors E7449 Phase 1, Phase 2 Recruiting
Study to assess the efficacy and safety of a PARP Inhibitor for the treatment of BRCA-positive advanced ovarian cancer AZD2281 Phase 2 Completed
Rucaparib(CO-338;Formally Called AG-014699 or PF-0136738) in treating patients with locally advanced or metastatic breast cancer or advanced ovarian cancer Rucaparib Phase 2 Recruiting
Olaparib in combination with carboplatin for refractory or recurrent women's cancers Olaparib Phase 1 Recruiting
Study to assess the safety and tolerability of a parp inhibitor in combination with carboplatin and/or paclitaxel AZD2281 Phase 1 Active, not recruiting
Dose-finding study comparing efficacy and safety of a PARP inhibitor against Doxil in BRCA+ve advanced ovarian cancer AZD2281 Phase 2 Active, not recruiting
A study of MK4827 in participants with advanced solid tumors or hematologic malignancies (MK-4827-001 AM8) MK-4827 Phase 1 Completed
Study to compare the efficacy and safety of Olaparib when given in combination with Carboplatin and Paclitaxel, compared with Carboplatin and Paclitaxel in patients with advanced ovarian cancer Olaparib Phase 2 Active, not recruiting
Phase I of BKM120/Olaparib for triple negative breast cancer or high grade serous ovarian cancer BKM120 and Olaparib Phase 1 Recruiting
Veliparib and Topotecan Hydrochloride in treating patients with solid tumors, relapsed or refractory ovarian cancer, or primary peritoneal cancer Veliparib Phase 1, Phase 2 Recruiting
Phase II study of AZD2281 in patients with known BRCA mutation status or recurrent high grade ovarian cancer or Patients with known BRCA mutation status/triple neg breast cancer AZD2281 Phase 2 Active, not recruiting
Veliparib and pegylated liposomal doxorubicin hydrochloride in treating patients with recurrent ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer Veliparib Phase 1 Recruiting
A study of Oral Rucaparib in Patients with a Solid Tumor (Phase I) or with gBRCA Mutation Ovarian Cancer (Phase II) Rucaparib Phase 1, Phase 2 Recruiting
Veliparib Monotherapy for Relapsed Ovarian Cancer with BRCA Mutation Veliparib Phase 1, Phase 2 Recruiting
Olaparib treatment in BRCA mutated ovarian cancer Patients After Complete or Partial Response to Platinum Chemotherapy Olaparib 300 mg tablets Phase 3 Not yet recruiting
Olaparib Monotherapy in Patients with BRCA mutated ovarian cancer following first line platinum based chemotherapy Olaparib 300 mg tablets Phase 3 Not yet recruiting
Assessment of efficacy of AZD2281 in platinum sensitive relapsed serous ovarian cancer AZD2281 Phase 2 Completed
A study of Rucaparib in patients with platinum-sensitive, relapsed, high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer (ARIEL2) Oral Rucaparib Phase 2 Not yet recruiting
Study of BMN 673, a PARP Inhibitor, in Patients with Advanced or Recurrent Solid Tumors BMN 673 Phase 1 Recruiting
ABT-888 with Cyclophosphamide in Refractory BRCA-Positive ovarian, primary peritoneal or ovarian high-grade serous carcinoma, fallopian tube cancer, triple-negative breast cancer, and low-grade non-hodgkin's lymphoma ABT-888 Phase 2 Active, not recruiting
A Phase I study of ABT-888 in combination with Temozolomide in Cancer Patients ABT-888 Phase 1 Completed
Veliparib, Cisplatin, and Vinorelbine Ditartrate in treating patients with Recurrent and/or Metastatic Breast Cancer Veliparib Phase 1 Recruiting
Single arm study of BSI-201 in Patients with BRCA-1 or BRCA-2 associated advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer Iniparib Phase 2 Completed
Veliparib in treating patients with malignant solid tumors that did not respond to previous therapy Veliparib Phase 1 Recruiting
Veliparib and Floxuridine in treating patients with metastatic epithelial ovarian, primary peritoneal cavity, or fallopian tube cancer Veliparib Phase 1 Recruiting
Veliparib in treating patients with persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer Veliparib Phase 2 Active, not recruiting
Carboplatin, Paclitaxel, Bevacizumab, and ABT-888 in treating patients with newly diagnosed Stage II, Stage III, or Stage IV ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer Veliparib Phase 1 Recruiting
Cediranib and Olaparib in combination for recurrent ovarian or Triple-Negative Breast Cancer Olaparib, Cediranib Phase 1, Phase 2 Active, not recruiting
Open label study to assess efficacy and safety of Olaparib in confirmed genetic BRCA1 or BRCA2 mutation pats Olaparib Phase 2 Active, not recruiting
Table 2: Ongoing studies of PARP inhibitor in ovarian cancer [50].